Pathogenesis of hepatitis C-associated hepatocellular carcinoma
Pathogenesis of hepatitis C-associated hepatocellular carcinoma
复制标题
DOI：
10.1053/j.gastro.2004.09.017
复制
发表时间：
2004-11-01
期刊：
影响因子：
29.4
通讯作者：
Heller, T
中科院分区：
文献类型：
--
作者：
Liang, TJ;Heller, T
流行病学、临床和病毒学数据显示，丙型肝炎病毒（HCV）慢性感染与肝细胞癌（HCC）的发生密切相关。在许多发达国家，HCV感染占HCC病例的一半以上。HCC通常在感染2-4年后出现，通常在基础肝硬化的背景下。用干扰素α治疗丙型肝炎可以持续清除HCV，小型前瞻性研究以及较大的回顾性分析表明，干扰素治疗可以降低HCC的发病率。由于没有可靠的组织培养系统或HCV感染的小动物模型，很难分析HCV导致癌症的机制。然而，体外表达系统和体内转基因小鼠研究均表明HCV具有固有的致癌潜力。了解HCV相关性HCC的发病机制对于开发预防和治疗这种高度恶性的癌症的有效方法非常重要。
Epidemiologic, clinical, and virologic data have shown a close association between chronic infection with hepatitis C virus (HCV) and the development of hepatocellular carcinoma (HCC). In many countries of the developed world, HCV infection accounts for more than half of the cases of HCC. HCC usually arises after 2-4 decades of infection, typically in the context of an underlying cirrhosis. Treatment of hepatitis C with interferon-alfa can lead to sustained clearance of HCV, and small prospective studies as well as larger retrospective analyses suggest that interferon therapy leads to a decrease in the incidence of HCC. Without a reliable tissue culture system or a small animal model of HCV infection, analysis of the mechanisms by which HCV leads to cancer has been difficult. Nevertheless, both in vitro expression systems and in vivo transgenic mice studies suggest that HCV has an inherent carcinogenic potential. Understanding the pathogenesis of HCV-associated HCC Is important in developing effective means of prevention and treatment of this highly malignant form of cancer.